Navigation Links
Adamis Pharmaceuticals CEO Provides Update for Shareholders

SAN DIEGO, May 3, 2013 /PRNewswire/ -- Dennis J. Carlo, Ph.D., the President and Chief Executive Officer of Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, today provided the following letter to shareholders:

Dear Shareholder:

A number of stockholders have been asking me to comment on our developments; therefore I thought it might be appropriate to put my response in a letter to all of our shareholders.  We have been relatively quiet this past year, but at the same time, we have been busy trying to build our Company.  Results will speak for themselves, and we certainly have our challenges and obviously there are no assurances, but I am extremely excited and optimistic about our future.  Creating and developing the assets that we currently have has taken a considerable amount of time, dedication, effort and a "never give-up" attitude.  Having put many of the pieces of the puzzle together, I believe that we are poised to embark on a journey that will transform Adamis and could propel us to new levels.

We are laying the foundation to support a company that we believe has the potential to generate significant revenues, profits and shareholder value.  In both the specialty pharmaceutical and biotechnology areas, we have a platform technology, a clear business and financial model, an experienced management team, significant intellectual property, and very large (in some cases, billion dollar) potential markets for our product candidates.

This year our current objectives include:

  • Focusing on submitting our single dose epinephrine syringe for regulatory approval and sale next year
  • Completing the manufacture of our Beclomethasone-HFA product to initiate Phase III studies in asthma and COPD
  • Finalizing our allergic rhinitis product development in order to initiate Phase III clinical trials
  • Acquiring or in-licensing an established product or technology that, following regulatory marketing approvals, will compete in large (multi-billion dollar) product markets and will be synergistic with our existing assets.

On the Biotech side, we are focused on:

  • Completing our Phase I prostate cancer drug trial
  • Finalizing the activities necessary to begin a Phase I/II trial for our second prostate compound
  • Initiating a Phase II prostate cancer vaccine trial for TeloB-VAX.

If we are able to complete additional financing transactions and make progress on our objectives, we intend to take the necessary steps to be in a position to list our common stock on a national stock exchange such as the NYSE-Amex or NASDAQ.  An up-listing could lead to an increase in shareholder value, give Adamis more market exposure, increase liquidity and partnering activities and increase our shareholder base to include more fundamental health care investors.

I would like to thank all of our shareholders for their continued support and patience.  We will all do our very best to make Adamis a company that you will all be very proud of owning.

Best regards,

Dennis J. Carlo , Ph.D
President and CEO

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology.  Products in its specialty pharmaceutical pipeline include the Epinephrine Injection PFS syringe for use in the emergency treatment of anaphylaxis, APC-1000 for the treatment of asthma and chronic obstructive pulmonary disease, and APC-3000, a HFA inhaled nasal steroid product for the treatment of allergic rhinitis.  Product candidates currently in development within its biotechnology division include TeloB-VAX, a novel cell-based therapeutic cancer vaccine, and three drug product candidates, APC-100, APC-200, and APC-300, for the treatment of prostate cancer and inflammation.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.  These statements relate to future events or our future results of operations or future financial performance, including, but not limited to the following statements: the ability to fund future product development and business operations; future revenues expected from any of the company's product candidates, assuming that they are developed and approved for marketing by the FDA and other regulatory authorities; our ability to complete any future acquisitions of products, product candidates or technologies; and the intellectual property protection that may be afforded by any patents or patent applications relating to the company's technology.  Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis' filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site at  Except as required by law, Adamis expressly disclaims any obligation to update any forward-looking statements.

Related Links:

For Additional Information

David Marguglio
Senior Vice President, Corporate Development
Adamis Pharmaceuticals Corp.
Tel:  858- 412-7950

SOURCE Adamis Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
2. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
3. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
4. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
5. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
6. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
7. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
8. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
9. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
10. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
11. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
Post Your Comments:
(Date:11/30/2015)... Partnership includes an MPP ... u niversity , s Solid Drug Nanoparticle (SDN) Technology ... - up through cost cuts of ... where licensees based anywhere in the world will have the right to make, use ... , where licensees based anywhere in the world will have the right to ...
(Date:11/30/2015)... , Nov. 30, 2015 Spherix Incorporated ... committed to the fostering and monetization of intellectual ... and prospective initiatives designed to create shareholder value. ... Officer of Spherix. "Based on published reports, the ... exceeds $50 billion and Spherix will seek to ...
(Date:11/30/2015)... 2015 TapImmune, Inc. (TPIV), ... innovative peptide and gene-based immunotherapeutics and vaccines for the ... will be presenting at the 8 th Annual ... 2.30 PM PT. Dr. John N. Bonfiglio ... giving the presentation and will join TapImmune management in ...
(Date:11/30/2015)... Florida and MAGDEBURG, Germany , ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... 3rd European Congress of NeuroRehabilitation (ECNR) in ... --> NovaVision, a wholly owned subsidiary of Vycor ... European version of its Internet-delivered NovaVision Therapy Suite at the ...
Breaking Biology Technology:
(Date:10/29/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that it has been ... one of only three finalists for a 2015 ... Growing" category. The Tekne Awards honor Minnesota ... innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):